VYNE Therapeutics (VYNE) Non Operating Income (2016 - 2018)
VYNE Therapeutics (VYNE) posted Non Operating Income of $826000.0 for Q2 2018, up 46.71% on a QoQ basis from $563000.0 in Q1 2018, and up 1047.22% year-over-year from $72000.0 in Q2 2017.
VYNE Therapeutics (VYNE) Non Operating Income (2016 - 2018) Analysis & Trends
VYNE Therapeutics' Non Operating Income history runs 3 years deep, the most recent figure standing at $826000.0 for Q2 2018.
- Quarterly Non Operating Income rose 1047.22% year-over-year to $826000.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $1.8 million (changed N/A YoY) and the FY2017 annual result came in at $517000.0, up 95.83% from the prior year.
- Non Operating Income was $826000.0 for Q2 2018 at VYNE Therapeutics, up from $563000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $826000.0 in Q2 2018 and bottomed at $72000.0 in Q2 2017.
- A 3-year average of $284714.3 and a median of $163000.0 in 2017 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2017 — Non Operating Income surged 127.27% — and 2018, when it surged 1047.22%.
- VYNE Therapeutics' Non Operating Income stood at $88000.0 in 2016, then jumped by 127.27% to $200000.0 in 2017, then soared by 313.0% to $826000.0 in 2018.
- Business Quant data shows VYNE's Non Operating Income at $826000.0 in Q2 2018, $563000.0 in Q1 2018, and $200000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -8.59 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 826,000.00 |
| Mar 31, 2018 | 563,000.00 |
| Dec 31, 2017 | 200,000.00 |
| Sep 30, 2017 | 163,000.00 |
| Jun 30, 2017 | 72,000.00 |
| Mar 31, 2017 | 81,000.00 |
| Dec 31, 2016 | 88,000.00 |